Cancer Genetics Inc. (CGIX) Sets New 1-Year Low at $1.80
Cancer Genetics Inc. (NASDAQ:CGIX)’s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $1.80 and last traded at $2.01, with a volume of 107,422 shares. The stock had previously closed at $2.16.
Separately, Zacks Investment Research upgraded shares of Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Wednesday, May 11th.
The company’s 50-day moving average price is $2.04 and its 200-day moving average price is $2.33. The company’s market cap is $27.71 million.
Cancer Genetics (NASDAQ:CGIX) last released its earnings results on Wednesday, August 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The company earned $7 million during the quarter, compared to analysts’ expectations of $6.50 million. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Cancer Genetics’s revenue for the quarter was up 67.3% compared to the same quarter last year. On average, analysts predict that Cancer Genetics Inc. will post ($1.26) earnings per share for the current fiscal year.
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.